Chen Wang
Chen Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bing Chen
Department of Hematology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, People’s Republic of China
1 shared publication Bo Wang
Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518107, PR China
1 shared publicationEnxiu Wang
Nanjing CART Medical Technology Co., Ltd., Nanjing 210032, PR China
1 shared publication- Enxiu Wang
Clinical Pathological Diagnosis & Research Center, Youjiang Medical University for Nationalities
1 shared publication Jianping Hu
Nanjing CART Medical Technology Co. Ltd. Nanjing P.R. China
1 shared publicationJie Lin
Department of Pathology The Affiliated Hospital of Youjiang Medical University for Nationalities Baise P.R. China
1 shared publication
Latest Publications
- 2 January 2025
- Published by Wiley in Immunology
- Vol. 174 (3) , 310-321
Co‐Expression of Dominant‐Negative TGF‐β Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1/DAP12‐BB‐Based CAR‐T Cells in Solid Tumours
Chimeric antigen receptor (CAR) T‐cell therapy has exhibited remarkable efficacy in the treatment of haematological malignancies, yet its application in solid tumours is hindered by the immunosuppressive tumour microenvironment (TME). In this study, a novel SS1‐TREM1/DAP12‐BB CAR‐T cell was devised to target ovarian cancer and further engineered to co‐express the dominant‐negative TGF‐β receptor 2 (DNR) to combat CAR‐T cell exhaustion in TME. The incorporation of DNR effectively blocked TGF‐β signalling, thereby enhancing CAR‐T cell survival and antitumor activity in a TGF‐β1‐rich environment. In vivo evaluations demonstrated that DNR co‐expression potentiated the antitumor efficacy of TREM1/DAP12‐BB CAR‐T cells and conferred resilience against tumour rechallenge. These findings underscore the broad potential of DNR co‐expression in CAR design, presenting a novel therapeutic strategy for patients with recurrent ovarian cancer.
- 2 January 2025
- Published by Wiley in Immunology
- Vol. 174 (3) , 310-321
Co‐Expression of Dominant‐Negative TGF‐β Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1/DAP12‐BB‐Based CAR‐T Cells in Solid Tumours
Chimeric antigen receptor (CAR) T‐cell therapy has exhibited remarkable efficacy in the treatment of haematological malignancies, yet its application in solid tumours is hindered by the immunosuppressive tumour microenvironment (TME). In this study, a novel SS1‐TREM1/DAP12‐BB CAR‐T cell was devised to target ovarian cancer and further engineered to co‐express the dominant‐negative TGF‐β receptor 2 (DNR) to combat CAR‐T cell exhaustion in TME. The incorporation of DNR effectively blocked TGF‐β signalling, thereby enhancing CAR‐T cell survival and antitumor activity in a TGF‐β1‐rich environment. In vivo evaluations demonstrated that DNR co‐expression potentiated the antitumor efficacy of TREM1/DAP12‐BB CAR‐T cells and conferred resilience against tumour rechallenge. These findings underscore the broad potential of DNR co‐expression in CAR design, presenting a novel therapeutic strategy for patients with recurrent ovarian cancer.
- Open Access
- 28 August 2021
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 23, 96-106
Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL
- 28 August 2021
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 23, 96-106
Open AccessNovel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL